{"ATC Code":"N03AX16","Abbreviation":"","Aliases":["(S)-3-(Aminomethyl)-5-methylhexanoic acid","3-isobutyl GABA","(S)-Pregabalin","Pregabalina","Pregabaline","Vronogabic","Pregabalin mylan","Pregabalin sandoz","Pregabalin zentiva","Pregabalin sandoz gmbh"],"Biological Half-Life":"The elimination half life of pregabalin is 6.3 hours.","CAS":"148553-50-8","ChEBI":"CHEBI:64356","ChEMBL":"CHEMBL1059","ChemicalClasses":["gabapentinoid"],"Chirality":"absolute","Classes":null,"Color/Form":"White to off-white crystalline solid","DEA no":2782,"Drug Classes":"Breast Feeding; Lactation; Milk, Human; Analgesics; Anticonvulsants","Drug Indication":"Pregabalin is indicated for the management of neuropathic pain associated with diabetic peripheral neuropathy, postherpetic neuralgia, fibromyalgia, neuropathic pain associated with spinal cord injury, and as adjunctive therapy for the treatment of partial-onset seizures in patients 1 month of age and older.","Drug Warnings":"Known hypersensitivity to pregabalin or any ingredient in the formulation.","DrugClasses":["calcium channel blocker"],"DurationOfAction":"8 – 12 hours \u003ca href='#cite_note-6'\u003e\u003csup\u003e[6]\u003c/sup\u003e\u003c/a\u003e","EliminationHalfLife":"4.5 – 7 hours\u003ca href='#cite_note-4'\u003e\u003csup\u003e[4]\u003c/sup\u003e\u003c/a\u003e (mean 6.3 hours)\u003ca href='#cite_note-5'\u003e\u003csup\u003e[5]\u003c/sup\u003e\u003c/a\u003e","Erowid Experience Reports":[{"Id":"101373","Title":"Observations Over 4 Years of Usage"},{"Id":"101841","Title":"Amazing Time Slip"},{"Id":"103284","Title":"My Hellish Withdrawal"},{"Id":"103320","Title":"I Wish I Hadn't Redosed"},{"Id":"103385","Title":"Painless Time and Zoned Out"},{"Id":"103773","Title":"My Social Anxiety Has Been Obliterated"},{"Id":"106317","Title":"Long-Term Use and High Dosages"},{"Id":"106972","Title":"Closed Eye Visuals Similar to Lucid Dreaming"},{"Id":"107163","Title":"Wishing It Never Ended"},{"Id":"107573","Title":"All in Around 5 Years"},{"Id":"107816","Title":"On a Dose for a Traumatic Brain Injury"},{"Id":"108420","Title":"A Very Romantic Night With My Wife"},{"Id":"108870","Title":"Gentle and Smooth"},{"Id":"109599","Title":"Ghost In My Kitchen"},{"Id":"109511","Title":"Cannabis Type Buzz"},{"Id":"109464","Title":"The Journey Into Acceptance"},{"Id":"110435","Title":"Mildly Dissociative"},{"Id":"110327","Title":"Personal Effects Summary"},{"Id":"110999","Title":"I Can Alter the Scene-Flow"},{"Id":"111784","Title":"Cutting-Edge Pharmacology a Double-Edged Swor"},{"Id":"111963","Title":"Effects Peaked Around the Two Hour Mark"},{"Id":"112702","Title":"Body Warmth and Pleasantness of Mind"},{"Id":"112073","Title":"A Little Too Much"},{"Id":"114724","Title":"Zero Recreational Benefits"},{"Id":"114352","Title":"Maybe Mania"},{"Id":"115206","Title":"Seeing Infinity"}],"European Community (EC) Number":"604-639-1","FullSalts":["Pregabalin hydrochloride","Sodium pregabalin"],"HMDB ID":"HMDB0014375","HeavyAtomCount":11,"Human Drugs":"Breast Feeding; Lactation; Milk, Human; Analgesics; Anticonvulsants","IUPACName":"(3S)-3-(aminomethyl)-5-methylhexanoic acid","Impurities":["pregabalin lactam, (±)-","4,5-dehydro pregabalin, (r)-","isobutyl glutarmonoamide","isobutylglutaric acid","pregabalin, (r)-",".alpha.-d-tagatopyranose, 1-deoxy-1-((4s)-4-(2-methylpropyl)-2-oxo-1-pyrrolidinyl)-","(z)-2-cyano-5-methylhex-2-enamide","3-isobutylpyrrolidine-2,5-dione","2,4-dicyano-3-isobutylpentanediamide","(s)-3-(aminomethyl)-n,n-diethyl-5-methylhexanamide"],"InChI":"InChI=1S/C8H17NO2/c1-6(2)3-7(5-9)4-8(10)11/h6-7H,3-5,9H2,1-2H3,(H,10,11)/t7-/m0/s1","InChIKey":"AYXYPKUFHZROOJ-ZETCQYMHSA-N","MeSH Pharmacological Classification":"A class of drugs that act by selective inhibition of calcium influx through cellular membranes. (See all compounds classified as Calcium Channel Blockers.)","Melting Point":"186-188 °C","MolecularFormula":"C\u003csub\u003e8\u003c/sub\u003eH\u003csub\u003e17\u003c/sub\u003eNO\u003csub\u003e2\u003c/sub\u003e","MolecularWeight":"159.23 g/mol","Opticalactivity":"UNSPECIFIED","PD":"PD-144723","Pharmacodynamics":"Although the structure of pregabalin is similar to gamma-aminobutyric acid (GABA), it does not bind to GABA receptors. Instead, it binds the alpha2-delta subunit of presynaptic voltage-gated calcium channels in the central nervous system. Pregabalin does not modulate dopamine receptors, serotonin receptors, opiate receptors, sodium channels or cyclooxygenase activity.","Physical Description":"Solid","PrevSalts":["hydrochloride","sodium"],"PubChemId":5486971,"Record Description":["Pregabalin is a gamma-amino acid that is gamma-aminobutyric acid (GABA) carrying an isobutyl substitutent at the beta-position (the S-enantiomer). Binds with high affinity to the alpha2-delta site (an auxiliary subunit of voltage-gated calcium channels) in central nervous system tissues. It has a role as an anticonvulsant and a calcium channel blocker. It is functionally related to a gamma-aminobutyric acid.","Pregabalin is a DEA Schedule V controlled substance. Substances in the DEA Schedule V have a low potential for abuse relative to substances listed in Schedule IV and consist primarily of preparations containing limited quantities of certain narcotics. It is a Depressants substance.","Pregabalin is structurally similar to gamma-aminobutyric acid (GABA) - an inhibitory neurotransmitter. It may be used to manage neuropathic pain, postherpetic neuralgia, and fibromyalgia among other conditions. Although as per the FDA Label the mechanism of action has not been definitively characterized, there is evidence that pregabalin exerts its effects by binding to the α2δ subunit of voltage-dependent calcium channels. Pregabalin is marketed by Pfizer under the trade name Lyrica and Lyrica Cr (extended release). It may have dependence liability if misused but the risk appears to be highest in patients with current or past substance use disorders.","Pregabalin is an inhibitor of neuronal activity used for therapy of painful neuropathy and as an anticonvulsant. Therapy with pregabalin is not associated with serum aminotransferase elevations, and clinically apparent liver injury from pregabalin has been reported but appears to be quite rare.","Pregabalin is a 3-isobutyl derivative of gamma-amino butyric acid (GABA) with anti-convulsant, anti-epileptic, anxiolytic, and analgesic activities. Although the exact mechanism of action is unknown, pregabalin selectively binds to alpha2delta (A2D) subunits of presynaptic voltage-dependent calcium channels (VDCCs) located in the central nervous system (CNS). Binding of pregabalin to VDCC A2D subunits prevents calcium influx and the subsequent calcium-dependent release of various neurotransmitters, including glutamate, norepinephrine, serotonin, dopamine, and substance P, from the presynaptic nerve terminals of hyperexcited neurons; synaptic transmission is inhibited and neuronal excitability is diminished. Pregabalin does not bind directly to GABA-A or GABA-B receptors and does not alter GABA uptake or degradation.","PREGABALIN is a small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2004 and has 9 approved and 45 investigational indications.","A gamma-aminobutyric acid (GABA) derivative that functions as a CALCIUM CHANNEL BLOCKER and is used as an ANTICONVULSANT as well as an ANTI-ANXIETY AGENT. It is also used as an ANALGESIC in the treatment of NEUROPATHIC PAIN and FIBROMYALGIA.","See also: Pregabalin hydrochloride (is active moiety of); Pregabalin Arenacarbil (is active moiety of).","Pregabalin is a gamma-amino acid that is gamma-aminobutyric acid (GABA) carrying an isobutyl substitutent at the beta-position (the S-enantiomer). Binds with high affinity to the alpha2-delta site (an auxiliary subunit of voltage-gated calcium channels) in central nervous system tissues. It has a role as an anticonvulsant and a calcium channel blocker. It is functionally related to a gamma-aminobutyric acid.","LiverTox|CNS|Anticonvulsant|GABA analogue"],"RefCount":7,"References":[{"Name":"Wikipedia","Urls":[{"Link":"https://en.wikipedia.org/wiki/Pregabalin","Name":"Pregabalin","Sub":false}]},{"Name":"Wikidata","Urls":[{"Link":"https://www.wikidata.org/wiki/Q412174","Name":"Pregabalin","Sub":false}]},{"Name":"DrugBank","Urls":[{"Link":"https://go.drugbank.com/drugs/DB00230","Name":"Pregabalin","Sub":false}]},{"Name":"PubChem","Urls":[{"Link":"https://pubchem.ncbi.nlm.nih.gov/compound/5486971","Name":"Pregabalin","Sub":false}]},{"Name":"ChEMBL","Urls":[{"Link":"https://www.ebi.ac.uk/chembl/explore/compound/CHEMBL1059","Name":"Pregabalin","Sub":false}]},{"Name":"ChEBI","Urls":[{"Link":"https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:64356","Name":"Pregabalin","Sub":false}]},{"Name":"Probes \u0026 Drugs","Urls":[{"Link":"https://www.probes-drugs.org/compound/PD-144723","Name":"Pregabalin","Sub":false}]},{"Name":"Common Chemistry","Urls":[{"Link":"https://commonchemistry.cas.org/detail?cas_rn=148553-50-8","Name":"Pregabalin","Sub":false}]},{"Name":"HMDB","Urls":[{"Link":"https://hmdb.ca/metabolites/HMDB0014375","Name":"Pregabalin","Sub":false}]},{"Name":"KEGG","Urls":[{"Link":"https://www.kegg.jp/entry/D02716","Name":"Pregabalin","Sub":false}]},{"Name":"UNII","Urls":[{"Link":"https://gsrs.ncats.nih.gov/ginas/app/ui/substances/55JG375S6M","Name":"Pregabalin","Sub":false}]},{"Name":"EPA DSSTox","Urls":[{"Link":"https://comptox.epa.gov/dashboard/chemical/details/DTXSID1045950","Name":"Pregabalin","Sub":false}]}],"Refs":["National Center for Biotechnology Information. PubChem Compound Summary for CID 5486971, Pregabalin. Accessed June 26, 2025. \u003ca href=https://pubchem.ncbi.nlm.nih.gov/compound/5486971\u003ehttps://pubchem.ncbi.nlm.nih.gov/compound/5486971\u003c/a\u003e","U.S. Food and Drug Administration; National Center for Advancing Translational Sciences. Pregabalin. UNII: 55JG375S6M. Global Substance Registration System. Accessed June 26, 2025. \u003ca href=https://gsrs.ncats.nih.gov/ginas/app/beta/substances/55JG375S6M\u003ehttps://gsrs.ncats.nih.gov/ginas/app/beta/substances/55JG375S6M\u003c/a\u003e","Prescription medicines: registration of new generic medicines and biosimilar medicines, 2017. June 21, 2022. Accessed June 26, 2025. \u003ca href=https://www.tga.gov.au/resources/publication/publications/prescription-medicines-registration-new-generic-medicines-and-biosimilar-medicines-2017\u003ehttps://www.tga.gov.au/resources/publication/publications/prescription-medicines-registration-new-generic-medicines-and-biosimilar-medicines-2017\u003c/a\u003e","Expert Committee on Drug Dependence Forty-first Meeting. Critical Review Report: Pregabalin. World Health Organization. November 1, 2018. Accessed June 26, 2025. \u003ca href=https://www.who.int/medicines/access/controlled-substances/Pregabalin_FINAL.pdf?ua=1\u003ehttps://www.who.int/medicines/access/controlled-substances/Pregabalin_FINAL.pdf?ua=1\u003c/a\u003e","Cross AL, Viswanath O, Sherman AI. StatPearls [Internet]. StatPearls Publishing. July 19, 2022. Accessed June 26, 2025. \u003ca href=https://www.ncbi.nlm.nih.gov/books/NBK470341/\u003ehttps://www.ncbi.nlm.nih.gov/books/NBK470341/\u003c/a\u003e","BNF Pregabalin. NICE. November 16, 2018. Accessed June 26, 2025. \u003ca href=https://bnf.nice.org.uk/drugs/pregabalin/#indications-and-dose\u003ehttps://bnf.nice.org.uk/drugs/pregabalin/#indications-and-dose\u003c/a\u003e"],"SMILES":"CC(C)C[C@@H](CC(=O)O)CN","Salts":["hydrochloride","sodium"],"SaltsAcidCount":[1,1],"SaltsAmineCount":[1,1],"SaltsUNII":["8348PZ4JYW","3DA4H8E58A"],"Scheduling":[{"gov":"Australia","ref":["3"],"schedule":"S4 substance"},{"gov":"Brazil","ref":[],"schedule":"C1 substance"},{"gov":"Canada","ref":[],"schedule":"prescription only substance"},{"gov":"New Zealand","ref":[],"schedule":"prescription only substance"},{"gov":"United Kingdom","ref":[],"schedule":"prescription only substance"},{"gov":"United States","ref":[],"schedule":"Schedule V substance"},{"gov":"European Union","ref":[],"schedule":"prescription only substance"}],"Solubility":"Freely soluble","StoreUNII":["55JG375S6M"],"StructureBase64":"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","Subjective Effects":null,"Therapeutic Uses":"Pregabalin is indicated for management of post-herpetic neuralgia. /Included in US product label/","Title":"Pregabalin","UNII":"55JG375S6M","Wikidata":"Q412174","Wikipedia":"Pregabalin","XLogP":-1.6}